HC Wainwright Analysts Increase Earnings Estimates for DWTX

Dogwood Therapeutics, Inc (NASDAQ:DWTX) – Stock analysts at HC Wainwright upped their FY2029 earnings per share (EPS) estimates for Dogwood Therapeutics in a research report issued on Monday, November 10th. HC Wainwright analyst S. Lee now expects that the company will post earnings of $1.13 per share for the year, up from their previous estimate of $1.12. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($6.43) per share.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Dogwood Therapeutics in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Dogwood Therapeutics currently has a consensus rating of “Hold” and an average target price of $12.00.

Dogwood Therapeutics Price Performance

Shares of NASDAQ:DWTX opened at $5.83 on Tuesday. The company’s fifty day moving average price is $5.73 and its 200-day moving average price is $5.22. The firm has a market capitalization of $13.35 million, a price-to-earnings ratio of -0.23 and a beta of 1.86. Dogwood Therapeutics has a one year low of $1.62 and a one year high of $29.28.

Dogwood Therapeutics (NASDAQ:DWTX) last announced its earnings results on Thursday, November 6th. The company reported ($8.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($6.97).

Dogwood Therapeutics Company Profile

Dogwood Therapeutics, Inc is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia.